间质性膀胱炎的治疗策略

庞阳阳; 龚玉雯; 刘伟; 田跃军; 王志平

doi:10.13201/j.issn.1001-1420.2017.05.019

间质性膀胱炎的治疗策略

- 兰州大学第二医院泌尿外科研究所, 甘肃省泌尿系统疾病研究重点实验室(兰州大学), 省泌尿系统疾病临床医学中心, (兰州, 730000)

详细信息

通讯作者: 王志平,E-mail:erywzp@lzu.edu.cn

中图分类号: R694

收稿日期: 2016-12-31

Treatment strategies for interstitial cystitis

- Institute of Urology of Lanzhou University Second Hospital, Gansu Province Key Laboratory of Urological Diseases of Lanzhou University, Gansu Nephro-Urological Clinical Center, Lanzhou, 730000, China

More Information

Corresponding author: WANG Zhiping, E-mail: erywzp@lzu.edu.cn

Received Date: 31 December 2016

摘要

摘要: 间质性膀胱炎是一种不明病因的慢性异质性疾病,使很大一部分女性受累。患者的症状高度可变:可能会遭受骨盆疼痛而且疼痛会由于膀胱的充盈而加剧,并且会伴随有一系列的下尿路症状,包括尿频和尿急。考虑到不同患者临床表现并不完全相同,因此应该针对每个具体的患者给予相应的治疗。目前美国泌尿协会(AUA)指南将IC治疗分为6个层次,建议开始对患者进行教育以及改善生活方式,再通过物理、药物治疗,对于那些前期治疗均失败的患者最终进行手术治疗。这篇文章针对IC最新治疗指南以及这些指南的一些证据资料进行了综述。
- 间质性膀胱炎 /
- 膀胱疼痛综合征 /
- 治疗
Abstract: Interstitial cystitis(IC)is a chronic heterogeneous disease of unknown etiology with a large amount of women involvement.Patients' symptoms are highly variable.They may suffer from pelvic pain which will be aggravated by bladder filling,and can be accompanied by a series of lower urinary tract symptoms,including frequency and urgency.Because of the varying clinical manifestations,a corresponding treatment should be tailored to each individual patient.Current American Urological Association(AUA)guidelines divided IC treatment recommendations into six levels.It is firstly recommended that patients be educated and improve their lifestyles.Then physical and drug therapy should be performed.For patients who have failed previous treatments shall eventually undergo surgery.This article has reviewed the latest treatment recommendations for IC and the evidence from which these recommendations arise.
- interstitial cystitis /
- bladder pain syndrome /
- therapy

HTML全文

参考文献(33)

[1]	Berry S H,Elliott M N,Suttorp M,et al.Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States[J].J Urol,2011,186(2):540-544.
[2]	Hanno P M,Burks D A,Clemens J Q,et al.AUAguideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome[J].J Urol,2011,185(6):2162-2170.
[3]	Hanno P M,Erickson D,Moldwin R,et al.Diagnosis and treatment of interstitial cystitis/bladder pain syndrome:AUA guideline amendment[J].J Urol,2015,193(5):1545-1553.
[4]	Fitzgerald M P,Payne C K,Lukacz E S,et al.Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness[J].J Urol,2012,187(6):2113-2118.
[5]	van Ophoven A,Pokupic S,Heinecke A,et al.A prospective,randomized,placebo controlled,double-blind study of amitriptyline for the treatment of interstitial cystitis[J].J Urol,2004,172(2):533-536.
[6]	van Ophoven A,Hertle L.Long-term results ofamitriptyline treatment for interstitial cystitis[J].J Urol,2005,174(5):1837-1840.
[7]	Barr S.Diagnosis and management of interstitial cystitis[J].Obstet Gynecol Clin North Am,2014,41(3):397-407.
[8]	Thilagarajah R,Witherow R O,Walker M M.Oral cimetidine gives effective symptom relief in painful bladder disease:aprospective,randomized,double-blind placebo-controlled trial[J].BJU Int,2001,87(3):207-212.
[9]	Sant G R,Propert K J,Hanno P M,et al.A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis[J].JUrol,2003,170(3):810-815.
[10]	Janssen D A,van Wijk X M,Jansen K C,et al.The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier[J].JUrol,2013,189(1):336-342.
[11]	Nickel J C,Herschorn S,Whitmore K E,et al.Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome:insights from a randomized,double-blind,placebo controlled study[J].JUrol,2015,193(3):857-862.
[12]	Sairanen J,Tammela T L,Leppilahti M,et al.Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis:a randomized comparative study[J].J Urol,2005,174(6):2235-2238.
[13]	Sairanen J,Forsell T,Ruutu M.Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A[J].J Urol,2004,171(6 Pt 1):2138-2141.
[14]	Ehren I,Hallen G K,Vrba M,et al.Nitric oxide as a marker for evaluation of treatment effect of cyclosporine A in patients with bladder pain syndrome/interstitial cystitis type 3C[J].Scand J Urol,2013,47(6):503-508.
[15]	Colaco M A,Evans R J.Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome[J].Curr Urol Rep,2013,14(5):442-447.
[16]	Moldwin R M,Evans R J,Stanford E J,et al.Rational approaches to the treatment of patients with interstitial cystitis[J].Urology,2007,69(4 Suppl):73-81.
[17]	Stav K,Beberashvili I,Lindner A,et al.Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis[J].Urology,2012,80(1):61-65.
[18]	Slobodov G,Feloney M,Gran C,et al.Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis[J].J Urol,2004,171(4):1554-1558.
[19]	Kyker K D,Coffman J,Hurst R E.Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder[J].BMC Urol,2005,5:4.
[20]	Campbell N A,Reece J B.Campbell biology[M].9th ed.ed.Boston:Benjamin Cummings/Pearson,2011.1263.
[21]	Nickel J C,Moldwin R,Lee S,et al.Intravesical alkalinized lidocaine(PSD597)offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome[J].BJU Int,2009,103(7):910-918.
[22]	Nickel J C,Jain P,Shore N,et al.Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome:safety and efficacy of a new drug delivery device[J].Sci Transl Med,2012,4(143):100r-143r.
[23]	Niimi A,Nomiya A,Yamada Y,et al.Hydrodistension with or without fulguration of hunner lesions forinterstitial cystitis:Long-term outcomes and prognostic predictors[J].Neurourol Urodyn,2016,35(8):965-969.
[24]	Hsieh C H,Chang W C,Huang M C,et al.Hydrodistention plus bladder training versus hydrodistention for the treatment of interstitial cystitis[J].Taiwan J Obstet Gynecol,2012,51(4):591-595.
[25]	Aihara K,Hirayama A,Tanaka N,et al.Hydrodistension under local anesthesia for patients with suspected painful bladder syndrome/interstitial cystitis:safety,diagnostic potential and therapeutic efficacy[J].Int JUrol,2009,16(12):947-952.
[26]	Payne R A,O'Connor R C,Kressin M,et al.Endoscopic ablation of Hunner's lesions in interstitial cystitis patients[J].Can Urol Assoc J,2009,3(6):473-477.
[27]	Hillelsohn J H,Rais-Bahrami S,Friedlander J I,et al.Fulguration for Hunner ulcers:long-term clinical outcomes[J].J Urol,2012,188(6):2238-2241.
[28]	Smith C P,Radziszewski P,Borkowski A,et al.Botulinum toxin a has antinociceptive effects in treating interstitial cystitis[J].Urology,2004,64(5):871-875.
[29]	Kuo H C.Preliminary results of suburothelialinjection of botulinum a toxin in the treatment of chronic interstitial cystitis[J].Urol Int,2005,75(2):170-174.
[30]	Giannantoni A,Costantini E,Di Stasi S M,et al.Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome:apilot study[J].Eur Urol,2006,49(4):704-709.
[31]	Ramsay A K,Small D R,Conn I G.Intravesical botulinum toxin type A in chronic interstitial cystitis:results of a pilot study[J].Surgeon,2007,5(6):331-333.
[32]	Liu H T,Tyagi P,Chancellor M B,et al.Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment[J].BJU Int,2009,104(10):1476-1481.
[33]	Kuo H C,Chancellor M B.Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome[J].BJU Int,2009,104(5):657-661.